APM
RGNX icon

Avidity Partners Management’s Regenxbio RGNX Stock Holding History

Avidity Partners Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-260,000
Closed -$1.86M – 80
2025
Q1 		$1.86M Sell
260,000
-272,000
-51% -$2.02M 0.35% 57
2024
Q4 		$4.11M Sell
532,000
-600,564
-53% -$5.64M 0.4% 52
2024
Q3 		$11.9M Sell
1,132,564
-167,500
-13% -$2.04M 0.61% 57
2024
Q2 		$15.2M Hold
1,300,064
– – 0.65% 56
2024
Q1 		$27.4M Buy
+1,300,064
New +$23.1M 0.88% 41

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Avidity Partners Management's RGNX Position: Q2 2025 in Review

Avidity Partners Management sold out of Regenxbio (RGNX) in Q2 2025, closing a stake of 260,000 shares — an estimated $1.86M sold.

Avidity Partners Management first reported a position in RGNX in Q1 2024 and held it in 5 quarters. The position peaked at $27.4M in Q1 2024. 159 funds tracked by Wall St. Rank hold RGNX as of Q2 2025.

  • Avidity Partners Management reported no remaining Regenxbio position as of Q2 2025 after selling out during the quarter.
  • Avidity Partners Management sold 260,000 Regenxbio shares in Q2 2025, an estimated $1.86M.
  • Avidity Partners Management first reported a position in Regenxbio in Q1 2024 and held it in 5 quarters.
  • Avidity Partners Management's Regenxbio position peaked at $27.4M in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Regenxbio as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.